Eli Lilly's (LLY -1.00%) mealtime insulin product Humalog brought in a whopping $2.4 billion last year. This drug comprises more than 10% of the drugmaker's total revenue, but Humalog's longevity could be compromised by an upcoming patent expiration, stiff competition by diabetes specialist Novo Nodisk (NVO -0.29%), and more competition in the future if MannKind (MNKD -0.24%) can get Afrezza, an ultra-rapid and inhalable insulin, on the market. In this video, health-care analyst Max Macaluso dives into this drug's sales, and breaks down the competitive landscape for investors.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.